Simon Ekman

About me
Publications
Public outreach and news

About me

Simon Ekman was born in Umeå in 1971. He earned his medical degree and defended his doctoral thesis at Uppsala University in 2000. In 2002-2005 he completed his postdoc at Rudbeck Laboratory, Uppsala University, and in 2011-2012 he was a visiting research fellow at the University of Colorado, Denver, USA. He was appointed docent in 2015.

As a clinician, Simon Ekman has specialised in oncology since 2004. Up until 2015 he was active at Uppsala University Hospital and since 2015 he has been working as Chief Physician at Karolinska University Hospital.

Simon Ekman was appointed Professor of Oncology at Karolinska Institutet on 1 January, 2023.

Articles

Article: LUNG CANCER. 2024;192:107826
Trends in lung cancer survival in the Nordic countries 1990-2016: The NORDCAN survival studies
Lundberg FE; Ekman S; Johansson ALV; Engholm G; Birgisson H; Olafsdottir EJ; Morch LS; Johannesen TB; Andersson TM-L; Pettersson D; Seppa K; Virtanen A; Lambe M; Lambert PC
Article: EUROPEAN JOURNAL OF CANCER. 2024;202:114010
Fertility and reproductive concerns related to the new generation of cancer drugs and the clinical implication for young individuals undergoing treatments for solid tumors
Helgadottir H; Matikas A; Fernebro J; Frodin J-E; Ekman S; Rodriguez-Wallberg KA
Article: ACTA ONCOLOGICA. 2023;62(12):1808-1814
Real-world analysis of MET exon 14 mutations in non-small cell lung cancer: a retrospective study from two Swedish hospitals
Skribek M; Brunnstrom H; Oskarsdottir G; Grive MP; Aricak O; Planck M; Jatta K; Naserhojati H; de Flon FH; Ekman S
Article: LUNG CANCER. 2023;182:107292
Cerebrospinal fluid as a liquid biopsy for molecular characterization of brain metastasis in patients with non-small cell lung cancer
Tsakonas G; Tadigotla V; Chakrabortty SK; Stragliotto G; Chan D; Lewensohn R; Yu W; Skog JK; Hydbring P; Ekman S
Article: CLINICAL AND TRANSLATIONAL SCIENCE. 2023;16(6):955-965
Brain exposure of osimertinib in patients with epidermal growth factor receptor mutation non-small cell lung cancer and brain metastases: A positron emission tomography and magnetic resonance imaging study
Ekman S; Cselenyi Z; Varrone A; Jucaite A; Martin H; Schou M; Johnstrom P; Laus G; Lewensohn R; Brown AP; van der Aart J; Vishwanathan K; Farde L
Article: PLOS ONE. 2023;18(2):e0277708
Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors
Makrakis D; Rounis K; Tsigkas A-P; Georgiou A; Galanakis N; Tsakonas G; Ekman S; Papadaki C; Monastirioti A; Kontogianni M; Gioulbasanis I; Mavroudis D; Agelaki S
Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022;24(1):193
Matched Analyses of Brain Metastases versus Primary Non-Small Cell Lung Cancer Reveal a Unique microRNA Signature
Tsakonas G; Koulouris A; Kazmierczak D; Botling J; Ortiz-Villalon C; Nord H; Lindskog M; Sandelin M; Micke P; Hydbring P; Ekman S
Article: TRANSLATIONAL LUNG CANCER RESEARCH. 2022;11(12):2495-2506
Alectinib as first-line treatment for advanced ALK-positive non- small cell lung cancer in the real-world setting: preliminary analysis in a Chinese cohort
Zou Z; Gu Y; Liang L; Hao X; Fan C; Xin T; Zhao S; Liu Z; Guo Y; Ma K; Li H; Zhang C; Shan L; Zhang Y; Dong G; Peng Y; Shen F; Song X; Christopoulos P; van der Wekken AJ; Okuda K; Ekman S; Xing P; Li J
Article: JOURNAL OF EXTRACELLULAR VESICLES. 2022;11(11):e12277
Characterizing single extracellular vesicles by droplet barcode sequencing for protein analysis
Banijamali M; Hojer P; Nagy A; Haag P; Paz Gomero E; Stiller C; Kaminskyy VO; Ekman S; Lewensohn R; Karlstrom AE; Viktorsson K; Ahmadian A
Article: TRANSLATIONAL LUNG CANCER RESEARCH. 2022;11(10):2064-2078
Plasma RNA profiling unveils transcriptional signatures associated with resistance to osimertinib in EGFR T790M positive non-small cell lung cancer patients
Alexeyenko A; Brustugun OT; Eide IJZ; Gencheva R; Kosibaty Z; Lai Y; de Petris L; Tsakonas G; Grundberg O; Franzen B; Viktorsson K; Lewensohn R; Hydbring P; Ekman S
Article: CANCERS. 2022;14(14):3430
Ras-Related Protein Rab-32 and Thrombospondin 1 Confer Resistance to the EGFR Tyrosine Kinase Inhibitor Osimertinib by Activating Focal Adhesion Kinase in Non-Small Cell Lung Cancer
Kosibaty Z; Brustugun OT; Eide IJZ; Tsakonas G; Grundberg O; De Petris L; McGowan M; Hydbring P; Ekman S
Article: TRANSLATIONAL LUNG CANCER RESEARCH. 2022;11(6):953-963
Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials
Eide IJZ; Stensgaard S; Helland A; Ekman S; Mellemgaard A; Hansen KH; Cicenas S; Koivunen J; Gronberg BH; Sorensen BS; Brustugun OT
Article: TRANSLATIONAL LUNG CANCER RESEARCH. 2022;11(5):722-734
Elevated expression of miR-494-3p is associated with resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer
Kazmierczak D; Eide IJZ; Gencheva R; Lai Y; Lewensohn R; Tsakonas G; Grundberg O; de Petris L; McGowan M; Brustugun OT; Ekman S; Hydbring P
Article: TRANSLATIONAL LUNG CANCER RESEARCH. 2022;11(5):786-801
Identification of GPX4 as a therapeutic target for lung adenocarcinoma after EGFR-TKI resistance
Zhang C; Wang C; Yang Z; Bai Y; Shukuya T; Poh M-E; Ekman S; Li J; Xu Y; Deng S
Article: JOURNAL OF EXPERIMENTAL AND CLINICAL CANCER RESEARCH. 2022;41(1):91
HDAC7 promotes NSCLC proliferation and metastasis via stabilization by deubiquitinase USP10 and activation of β-catenin-FGF18 pathway
Guo K; Ma Z; Zhang Y; Han L; Shao C; Feng Y; Gao F; Di S; Zhang Z; Zhang J; Tabbo F; Ekman S; Suda K; Cappuzzo F; Han J; Li X; Yan X
Article: PLOS ONE. 2022;17(10):e0276703
Lung cancer prediction using machine learning on data from a symptom e-questionnaire for never smokers, formers smokers and current smokers
Nemlander E; Rosenblad A; Abedi E; Ekman S; Hasselstrom J; Eriksson LE; Carlsson AC
Article: FUTURE ONCOLOGY. 2022;18(2):205-214
Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005-2015): SCAN-LEAF study
Sorensen JB; Horvat P; Rosenlund M; Kejs AM; Patel D; Juarez-Garcia A; Lacoin L; Daumont MJ; Penrod JR; O'Donnell JC; Brustugun OT; Ekman S
Article: ACTA ONCOLOGICA. 2021;60(12):1565-1571
Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study
Eide IJZ; Grut H; Helland A; Ekman S; Sorensen JB; Hansen KH; Gronberg BH; Cicenas S; Koivunen JP; Mellemgaard A; Brustugun OT
Article: BIOSENSORS AND BIOELECTRONICS. 2021;193:113568
Multiplexed electrokinetic sensor for detection and therapy monitoring of extracellular vesicles from liquid biopsies of non-small-cell lung cancer patients
Cavallaro S; Haag P; Sahu SS; Berisha L; Kaminskyy VO; Ekman S; Lewensohn R; Linnros J; Viktorsson K; Dev A
Article: MOLECULAR ONCOLOGY. 2021;15(11):2941-2957
Multiplex immune protein profiling of fine-needle aspirates from patients with non-small-cell lung cancer reveals signatures associated with PD-L1 expression and tumor stage
Franzen B; Viktorsson K; Kamali C; Darai-Ramqvist E; Grozman V; Arapi V; Haag P; Kaminskyy VO; Hydbring P; Kanter L; Nyren S; Ekman S; De Petris L; Lewensohn R
Article: CLINICAL LUNG CANCER. 2021;22(4):e555-e562
Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer
Yu H; Brustugun OT; Ekman S; Botling J; La Fleur L; Micke P; Solberg S; Berglund A; Rivard C; Hirsch FR
Article: CANCERS. 2021;13(13):3151
High Density of NRF2 Expression in Malignant Cells Is Associated with Increased Risk of CNS Metastasis in Early-Stage NSCLC
Tsakonas G; Martin-Bernabe A; Rounis K; Moreno-Ruiz P; Botling J; De Petris L; Ylipaa A; Mezheyeuski A; Micke P; Ostman A; Ekman S
Article: JTO CLINICAL AND RESEARCH REPORTS. 2021;2(5):100165
Epidemiology and Survival Outcomes for Patients With NSCLC in Scandinavia in the Preimmunotherapy Era: A SCAN-LEAF Retrospective Analysis From the I-O Optimise Initiative
Ekman S; Horvat P; Rosenlund M; Kejs AM; Patel D; Juarez-Garcia A; Lacoin L; Daumont MJ; Penrod JR; Brustugun OT; Sorensen JB
Article: CANCERS. 2021;13(7):1562
Correlation of Clinical Parameters with Intracranial Outcome in Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Pd-1/Pd-L1 Inhibitors as Monotherapy
Rounis K; Skribek M; Makrakis D; De Petris L; Agelaki S; Ekman S; Tsakonas G
Article: EUROPEAN JOURNAL OF CANCER. 2021;145:245-254
Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors
Skribek M; Rounis K; Afshar S; Grundberg O; Friesland S; Tsakonas G; Ekman S; De Petris L
Article: CANCERS. 2021;13(4):922
Detection of Tumor-Associated Membrane Receptors on Extracellular Vesicles from Non-Small Cell Lung Cancer Patients via Immuno-PCR
Stiller C; Viktorsson K; Paz Gomero E; Haag P; Arapi V; Kaminskyy VO; Kamali C; De Petris L; Ekman S; Lewensohn R; Karlstrom AE
Article: CANCERS. 2020;12(12):E3707-3707
Outcome of Patients with NSCLC and Brain Metastases Treated with Immune Checkpoint Inhibitors in a 'Real-Life' Setting
Skribek M; Rounis K; Makrakis D; Agelaki S; Mavroudis D; De Petris L; Ekman S; Tsakonas G
Article: CLINICAL LUNG CANCER. 2020;21(6):e544-e546
Primary CNS Metastatic BRAF-mutated Lung Adenocarcinoma With Complete Intracranial Response to BRAF/MEK Inhibition
Tsakonas G; Grozman V; Ekman S
Article: CANCERS. 2020;12(7):E1804-1804
ALK-Brain Prognostic Index-Preliminary Study of a Prognostic Tool for Patients with ALK-Rearranged, Non-small Cell Lung Cancer and Brain Metastases
Tsakonas G; Kamali C; De Petris L; Friesland S; Lewensohn R; Ekman S
Article: EUROPEAN JOURNAL OF CANCER. 2020;132:24-34
An immune gene expression signature distinguishes central nervous system metastases from primary tumours in non-small-cell lung cancer
Tsakonas G; Lewensohn R; Botling J; Ortiz-Villalon C; Micke P; Friesland S; Nord H; Lindskog M; Sandelin M; Hydbring P; Ekman S
Article: DISEASES OF THE ESOPHAGUS. 2020;33(5):doz078
Association between time interval from neoadjuvant chemoradiotherapy to surgery and complete histological tumor response in esophageal and gastroesophageal junction cancer: a national cohort study
Klevebro F; Nilsson K; Lindblad M; Ekman S; Johansson J; Lundell L; Ndegwa N; Hedberg J; Nilsson M
Article: LUNG CANCER. 2020;143:27-35
Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)
Eide IJZ; Helland A; Ekman S; Mellemgaard A; Hansen KH; Cicenas S; Koivunen J; Gronberg BH; Brustugun OT
Article: JOURNAL OF THORACIC ONCOLOGY. 2019;14(12):2109-2119
Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report
Dingemans A-MC; Hendriks LEL; Berghmans T; Levy A; Hasan B; Faivre-Finn C; Giaj-Levra M; Giaj-Levra N; Girard N; Greillier L; Lantuejoul S; Edwards J; O'Brien M; Reck M; Smit EF; Van Schil P; Postmus PE; Ramella S; Lievens Y; Gaga M; Peled N; Scagliotti GV; Senan S; Paz-Ares L; Guckenberger M; McDonald F; Ekman S; Cufer T; Gietema H; Infante M; Dziadziuszko R; Peters S; Porta RR; Vansteenkiste J; Dooms C; de Ruysscher D; Besse B; Novello S
Article: LUNG CANCER. 2019;133:69-74
c-MET as a biomarker in patients with surgically resected non-small cell lung cancer
Tsakonas G; Botling J; Micke P; Rivard C; LaFleur L; Mattsson J; Boyle T; Hirsch FR; Ekman S
Article: FUTURE ONCOLOGY. 2019;15(14):1551-1563
I-O Optimise: a novel multinational real-world research platform in thoracic malignancies
Ekman S; Griesinger F; Baas P; Chao D; Chouaid C; O'Donnell JC; Penrod JR; Daumont M; Lacoin L; McKenney A; Khovratovich M; Munro REJ; Durand-Zaleski I; Johnsen SP
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2019;511(2):260-265
miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC
Lai Y; Kacal M; Kanony M; Stukan I; Jatta K; Kis L; Norberg E; Vakifahmetoglu-Norberg H; Lewensohn R; Hydbring P; Ekman S
Article: LUNG CANCER. 2018;124:45-52
Exosomal RNA-profiling of pleural effusions identifies adenocarcinoma patients through elevated miR-200 and LCN2 expression
Hydbring P; De Petris L; Zhang Y; Branden E; Koyi H; Novak M; Kanter L; Haag P; Hurley J; Tadigotla V; Zhu B; Skog J; Viktorsson K; Ekman S; Lewensohn R
Article: LUNG CANCER. 2018;122:180-186
Dose escalation to 84 Gy with concurrent chemotherapy in stage III NSCLC appears excessively toxic: Results from a prematurely terminated randomized phase II trial
Hallqvist A; Bergstrom S; Bjorkestrand H; Svard A-M; Ekman S; Lundin E; Holmberg E; Johansson M; Friesland S; Nyman J
Article: ACTA ONCOLOGICA. 2018;57(2):231-238
Prognostic factors affecting survival after whole brain radiotherapy in patients with brain metastasized lung cancer
Tsakonas G; Hellman F; Gubanski M; Friesland S; Tendler S; Lewensohn R; Ekman S; de Petris L
Article: BMC RESEARCH NOTES. 2017;10(1):544
Synergistic effects of combining proteasome inhibitors with chemotherapeutic drugs in lung cancer cells.
Sooman L; Gullbo J; Bergqvist M; Bergström S; Lennartsson J; Ekman S
Article: GENES & DEVELOPMENT. 2017;31(20):2099-2112
RANK rewires energy homeostasis in lung cancer cells and drives primary lung cancer
Rao S; Sigl V; Wimmer RA; Novatchkova M; Jais A; Wagner G; Handschuh S; Uribesalgo I; Hagelkruys A; Kozieradzki I; Tortola L; Nitsch R; Cronin SJ; Orthofer M; Branstetter D; Canon J; Rossi J; D'Arcangelo M; Botling J; Micke P; La Fleur L; Edlund K; Bergqvist M; Ekman S; Lendl T; Popper H; Takayanagi H; Kenner L; Hirsch FR; Dougall W; Penninger J
Article: MODERN PATHOLOGY. 2017;30(7):964-977
Reaching the limits of prognostication in non-small cell lung cancer: an optimized biomarker panel fails to outperform clinical parameters.
Grinberg M; Djureinovic D; Brunnström HR; Mattsson JS; Edlund K; Hengstler JG; La Fleur L; Ekman S; Koyi H; Branden E; Ståhle E; Jirström K; Tracy DK; Pontén F; Botling J; Rahnenführer J; Micke P
Article: NEOPLASMA. 2017;64(6):909-915
The prognostic value of pre-treatment thrombocytosis in two cohorts of patients with non-small cell lung cancer treated with curatively intended chemoradiotherapy
Holgersson G; Bergstrom S; Hallqvist A; Liv P; Nilsson J; Willen L; Nyman J; Ekman S; Henriksson R; Bergqvist M
Article: PLOS ONE. 2017;12(11):e0187246
Integrative analysis of genome-wide gene copy number changes and gene expression in non-small cell lung cancer
Jabs V; Edlund K; Koenig H; Grinberg M; Madjar K; Rahnenfuehrer J; Ekman S; Bergkvist M; Holmberg L; Ickstadt K; Botling J; Hengstler JG; Micke P
Article: ANNALS OF ONCOLOGY. 2016;27(suppl 5):v1-v27
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Novello S; Barlesi F; Califano R; Cufer T; Ekman S; Levra MG; Kerr K; Popat S; Reck M; Senan S; Simo GV; Vansteenkiste J; Peters S
Article: JCI INSIGHT. 2016;1(10):e86837
Profiling cancer testis antigens in non-small-cell lung cancer
Djureinovic D; Hallstrom BM; Horie M; Mattsson JSM; La Fleur L; Fagerberg L; Brunnstrom H; Lindskog C; Madjar K; Rahnenfuehrer J; Ekman S; Stahle E; Koyi H; Branden E; Edlund K; Hengstler JG; Lambe M; Saito A; Botling J; Ponten F; Uhlen M; Micke P
Article: ACTA ONCOLOGICA. 2016;55(2):140-148
A novel oral insulin-like growth factor-1 receptor pathway modulator and its implications for patients with non-small cell lung carcinoma: A phase I clinical trial
Ekman S; Harmenberg J; Frodin J-E; Bergstrom S; Wassberg C; Eksborg S; Larsson O; Axelson M; Jerling M; Abrahmsen L; Hedlund A; Alvfors C; Stahl B; Bergqvist M
Article: ANTICANCER RESEARCH. 2015;35(10):5491-5497
Effect of Increased Radiotoxicity on Survival of Patients with Non-small Cell Lung Cancer Treated with Curatively Intended Radiotherapy
Holgersson G; Bergstrtom S; Liv P; Nilsson J; Edlund P; Blomberg C; Nyman J; Friesland S; Ekman S; Asklund T; Henriksson R; Bergqvist M
Article: ANTICANCER RESEARCH. 2015;35(7):3979-3985
Patients with Non-small Cell Lung Cancer Analyzed for EGFR: Adherence to Guidelines, Prevalence and Outcome.
Sandelin M; Berglund A; Sundström M; Micke P; Ekman S; Bergqvist M; Bergström S; Koyi H; Brandén E; Janson C; Botling J
Article: MEDICAL ONCOLOGY. 2015;32(4):129
A phase I pilot study of the insulin-like growth factor 1 receptor pathway modulator AXL1717 in combination with gemcitabine HCl and carboplatin in previously untreated, locally advanced, or metastatic non-small cell lung cancer.
Holgersson G; Bergström S; Harmenberg J; Ringbom M; Klockare M; Jerling M; Ekman S; Lundström KL; Koyi H; Brandén E; Larsson O; Bergqvist M
Article: ACTA ONCOLOGICA. 2015;54(3):385-394
FGF2 as a potential prognostic biomarker for proneural glioma patients
Sooman L; Freyhult E; Jaiswal A; Navani S; Edqvist P-H; Ponten F; Tchougounova E; Smits A; Elsir T; Gullbo J; Lennartsson J; Bergqvist M; Ekman S
Article: HEAD AND NECK. 2014;36(12):1727-1731
Time trends in T3 to T4 laryngeal cancer: a population-based long-term analysis.
Reizenstein JA; Holmberg L; Bergqvist M; Linder A; Ekman S; Lödén B; Holmqvist M; Hellström K; von Beckerath M; Blomquist E; Bergström SN
Article: INTERNATIONAL JOURNAL OF CANCER. 2014;135(9):2206-2214
Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer.
Micke P; Mattsson JSM; Edlund K; Lohr M; Jirström K; Berglund A; Botling J; Rahnenfuehrer J; Marincevic M; Pontén F; Ekman S; Hengstler J; Wöll S; Sahin U; Türeci O
Article: TUMOR BIOLOGY. 2014;35(5):4479-4488
PTPN6 expression is epigenetically regulated and influences survival and response to chemotherapy in high-grade gliomas.
Sooman L; Ekman S; Tsakonas G; Jaiswal A; Navani S; Edqvist P-H; Pontén F; Bergström S; Johansson M; Wu X; Blomquist E; Bergqvist M; Gullbo J; Lennartsson J
Article: INTERNATIONAL JOURNAL OF CANCER. 2014;134(5):1123-1131
A study of embryonic stem cell-related proteins in human astrocytomas: Identification of Nanog as a predictor of survival
Elsir T; Edqvist P-H; Carlson J; Ribom D; Bergqvist M; Ekman S; Popova SN; Alafuzoff I; Ponten F; Nister M; Smits A
Article: HISTOPATHOLOGY. 2014;64(3):365-379
Subtyping of gliomas of various WHO grades by the application of immunohistochemistry.
Popova SN; Bergqvist M; Dimberg A; Edqvist P-H; Ekman S; Hesselager G; Ponten F; Smits A; Sooman L; Alafuzoff I
Article: PLOS ONE. 2014;9(9):e108861
Human Cytomegalovirus Tegument Protein pp65 Is Detected in All Intra- and Extra-Axial Brain Tumours Independent of the Tumour Type or Grade
Libard S; Popova SN; Amini R-M; Karja V; Pietilainen T; Hamalainen KM; Sundstrom C; Hesselager G; Bergqvist M; Ekman S; Zetterling M; Smits A; Nilsson P; Pfeifer S; de Stahl TD; Enblad G; Ponten F; Alafuzoff I
Article: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2013;72(2):329-340
Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines.
Sooman L; Ekman S; Andersson C; Kultima HG; Isaksson A; Johansson F; Bergqvist M; Blomquist E; Lennartsson J; Gullbo J
Article: CANCER LETTERS. 2013;333(2):222-228
The prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer
Lohr M; Edlund K; Botling J; Hammad S; Hellwig B; Othman A; Berglund A; Lambe M; Holmberg L; Ekman S; Bergqvist M; Ponten F; Cadenas C; Marchan R; Hengstler JG; Rahnenfuehrer J; Micke P
Article: MEDICAL ONCOLOGY. 2013;30(1):320
The impact of hyperfractionated radiotherapy regimen in patients with non-small cell lung cancer
Holgersson G; Bergqvist M; Nyman J; Hoye E; Helsing M; Friesland S; Holgersson M; Ekberg L; Morth C; Ekman S; Blystad T; Ewers S-B; Loden B; Henriksson R; Bergstrom S
Article: MEDICAL ONCOLOGY. 2013;30(3):638
Vandetanib combined with a p38 MAPK inhibitor synergistically reduces glioblastoma cell survival.
Sooman L; Lennartsson J; Gullbo J; Bergqvist M; Tsakonas G; Johansson F; Edqvist P-H; Pontén F; Jaiswal A; Navani S; Alafuzoff I; Popova S; Blomquist E; Ekman S
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2013;42(1):297-304
Microtubule inhibition causes epidermal growth factor receptor inactivation in oesophageal cancer cells.
Wu X; Sooman L; Lennartsson J; Bergström S; Bergqvist M; Gullbo J; Ekman S
Article: CLINICAL CANCER RESEARCH. 2013;19(1):194-204
Biomarker Discovery in Non-Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation
Botling J; Edlund K; Lohr M; Hellwig B; Holmberg L; Lambe M; Berglund A; Ekman S; Bergqvist M; Ponten F; Koenig A; Fernandes O; Karlsson M; Helenius G; Karlsson C; Rahnenfuehrer J; Hengstler JG; Micke P
Article: BIOCHIMICA ET BIOPHYSICA ACTA: INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND BIOPHYSICS. 2012;1823(12):2130-2135
Telomerase antagonist imetelstat inhibits esophageal cancer cell growth and increases radiation-induced DNA breaks.
Wu X; Smavadati S; Nordfjäll K; Karlsson K; Qvarnström F; Simonsson M; Bergqvist M; Gryaznov S; Ekman S; Paulsson-Karlsson Y
Article: MEDICAL ONCOLOGY. 2012;29(5):3176-3182
Swedish lung cancer radiation study group: the prognostic value of anaemia, thrombocytosis and leukocytosis at time of diagnosis in patients with non-small cell lung cancer
Holgersson G; Sandelin M; Hoye E; Bergstrom S; Henriksson R; Ekman S; Nyman J; Helsing M; Friesland S; Holgersson M; Lundstrom KL; Janson C; Birath E; Morth C; Blystad T; Ewers S-B; Loden B; Bergqvist M
Article: INTERNATIONAL JOURNAL OF CANCER. 2012;131(10):2264-2273
CD99 is a novel prognostic stromal marker in non-small cell lung cancer
Edlund K; Lindskog C; Saito A; Berglund A; Ponten F; Goransson-Kultima H; Isaksson A; Jirstrom K; Planck M; Johansson L; Lambe M; Holmberg L; Nyberg F; Ekman S; Bergqvist M; Landelius P; Lamberg K; Botling J; Ostman A; Micke P
Article: BMC CANCER. 2012;12:318
Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma.
Dimberg LY; Dimberg A; Ivarsson K; Fryknäs M; Rickardson L; Tobin G; Ekman S; Larsson R; Gullberg U; Nilsson K; Öberg F; Wiklund HJ
Article: ACTA ONCOLOGICA. 2012;51(6):759-767
Swedish Lung Cancer Radiation Study Group: Predictive value of age at diagnosis for radiotherapy response in patients with non-small cell lung cancer
Holgersson G; Hoye E; Bergqvist M; Ekman S; Nyman J; Helsing M; Friesland S; Holgersson M; Ekberg L; Blystad T; Ewers S-B; Morth C; Loden B; Henriksson R; Bergstrom S
Article: ANTICANCER RESEARCH. 2012;32(4):1339-1346
The Value of Induction Chemotherapy for Survival in Patients with Non-small Cell Lung Cancer Treated with Radiotherapy
Holgersson G; Sandelin M; Hoye E; Bergstrom S; Henriksson R; Ekman S; Nyman J; Helsing M; Friesland S; Brodin O; Holgersson M; Lundstrom KL; Janson C; Ekberg L; Morth C; Blystad T; Ewers S-B; Loden B; Bergqvist M
Article: ACTA ONCOLOGICA. 2012;51(1):69-76
Expression of EGFR and LRIG proteins in oesophageal carcinoma with emphasis on patient survival and cellular chemosensitivity.
Wu X; Hedman H; Bergqvist M; Bergström S; Henriksson R; Gullbo J; Lennartsson J; Hesselius P; Ekman S
Article: EUROPEAN JOURNAL OF CANCER. 2011;47(16):2415-2421
Swedish Lung Cancer Radiation Study Group: Predictive value of histology for radiotherapy response in patients with non-small cell lung cancer
Holgersson G; Bergstrom S; Bergqvist M; Nyman J; Hoye E; Helsing M; Friesland S; Holgersson M; Birath E; Ekrnan S; Blystad T; Ewers S-B; Morth C; Loden B; Henriksson R
Article: JOURNAL OF THORACIC ONCOLOGY. 2011;6(11):1833-1840
Gene Copy Number Aberrations Are Associated with Survival in Histologic Subgroups of Non-small Cell Lung Cancer
Micke P; Edlund K; Holmberg L; Kultima HG; Mansouri L; Ekman S; Bergqvist M; Scheibenflug L; Lamberg K; Myrdal G; Berglund A; Andersson A; Lambe M; Nyberg F; Thomas A; Isaksson A; Botling J
Article: ACTA ONCOLOGICA. 2011;50(3):441-447
Clinical Phase I study with an Insulin-like Growth Factor-1 Receptor Inhibitor: Experiences in patients with squamous non-small cell lung carcinoma
Ekman S; Frodin J-E; Harmenberg J; Bergman A; Hedlund A; Dahg P; Alvfors C; Stahl B; Bergstrom S; Bergqvist M
Article: JOURNAL OF CHROMATOGRAPHY B: ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES. 2011;879(5-6):326-334
Determination of picropodophyllin and its isomer podophyllotoxin in human serum samples with electrospray ionization of hexylamine adducts by liquid chromatography-tandem mass spectrometry
Ronquist-Nii Y; Eksborg S; Axelson M; Harmenberg J; Beck O
Article: MELANOMA RESEARCH. 2010;20(6):468-478
SOX10 expression in superficial spreading and nodular malignant melanomas.
Agnarsdóttir M; Sooman L; Bolander A; Strömberg S; Rexhepaj E; Bergqvist M; Ponten F; Gallagher W; Lennartsson J; Ekman S; Uhlen M; Hedstrand H
Article: HEAD AND NECK. 2010;32(8):1062-1068
Impact of age at diagnosis on prognosis and treatment in laryngeal cancer.
Reizenstein JA; Bergström SN; Holmberg L; Linder A; Ekman S; Blomquist E; Lödén B; Holmqvist M; Hellström K; Nilsson CO; Brattström D; Bergqvist M
Article: IN VIVO. 2010;24(2):235-238
Dual-headed coincidence PET vs. dedicated PET/CT in the evaluation of thoracic malignancies.
Bergström S; Holgersson G; Bergqvist J-E; Bergqvist M; Ekman S; Stenström M
Article: CANCER GENOMICS AND PROTEOMICS. 2010;7(1):25-29
Mast cells in squamous cell esophageal carcinoma and clinical parameters.
Tinge B; Molin D; Bergqvist M; Ekman S; Bergström S
Article: CANCER GENOMICS AND PROTEOMICS. 2010;7(1):1-7
Molecular profiling using tissue microarrays as a tool to identify predictive biomarkers in laryngeal cancer treated with radiotherapy.
Holgersson G; Ekman S; Reizenstein J; Bergqvist M; Pontén F; Uhlén M; Magnusson K; Jonnalagadda P; Asplund A; Strömberg S; Linder A; Blomquist E; Liljeholm M; Lödén B; Hellström K; Bergström S
Article: PLOS ONE. 2009;4(6):e6057
Quantification of Normal Cell Fraction and Copy Number Neutral LOH in Clinical Lung Cancer Samples Using SNP Array Data
Goransson H; Edlund K; Rydaker M; Rasmussen M; Winquist J; Ekman S; Bergqvist M; Thomas A; Lambe M; Rosenquist R; Holmberg L; Micke P; Botling J; Isaksson A
Article: BRITISH JOURNAL OF CANCER. 2009;100(2):334-343
Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin.
Wu X; Wanders A; Wardega P; Tinge B; Gedda L; Bergstrom S; Sooman L; Gullbo J; Bergqvist M; Hesselius P; Lennartsson J; Ekman S
Article: MELANOMA RESEARCH. 2008;18(6):412-419
Serological and immunohistochemical analysis of S100 and new derivatives as markers for prognosis in patients with malignant melanoma
Bolander A; Agnarsdottir M; Wagenius G; Stromberg S; Ponten F; Ekman S; Brattstrom D; Larsson A; Einarsson R; Ullenhag G; Hesselius P; Bergqvist M
Article: ANTICANCER RESEARCH. 2007;27(5A):3211-3217
The role of circulating angiogenic factors in patients operated on for localized malignant melanoma.
Bolander A; Wagenius G; Larsson A; Brattström D; Ullenhag G; Hesselius P; Ekman S; Bergqvist M
Article: BLOOD. 2006;107(2):669-678
IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G₂/M-phase accumulation and apoptosis in multiple myeloma cells
Strömberg T; Ekman S; Girnita L; Dimberg LY; Larsson O; Axelson M; Lennartsson J; Hellman U; Carlson K; Österborg A; Vanderkerken K; Nilsson K; Jernberg-Wiklund H
Article: NEOPLASMA. 2006;53(4):285-290
Role of circulating cytokeratin fragments and angiogenic factors in NSCLC patients stage IIIa-IIIb receiving curatively intended treatment.
Eriksson P; Brattström D; Hesselius P; Larsson A; Bergström S; Ekman S; Goike H; Wagenius G; Brodin O; Bergqvist M
Article: BIOCHEMICAL JOURNAL. 2003;376(Pt 2):505-510
Ligand-induced recruitment of Na+/H+-exchanger regulatory factor to the PDGF (platelet-derived growth factor) receptor regulates actin cytoskeleton reorganization by PDGF.
Demoulin J-B; Seo JK; Ekman S; Grapengiesser E; Hellman U; Rönnstrand L; Heldin C-H
Article: ONCOGENE. 2002;21(12):1870-1875
SHP-2 is involved in heterodimer specific loss of phosphorylation of Tyr771 in the PDGF beta-receptor.
Ekman S; Kallin A; Engström U; Heldin C-H; Rönnstrand L
Article: BIOCHEMICAL JOURNAL. 1999;341 ( Pt 3)(Pt 3):523-528
Functional co-operation between the subunits in heterodimeric platelet-derived growth factor receptor complexes.
Emaduddin M; Ekman S; Rönnstrand L; Heldin CH
Article: ONCOGENE. 1999;18(15):2481-2488
Increased mitogenicity of an alphabeta heterodimeric PDGF receptor complex correlates with lack of RasGAP binding.
Ekman S; Thuresson ER; Heldin CH; Rönnstrand L
Article: ONCOGENE. 1998;16(10):1229-1239
Identification of Tyr-762 in the platelet-derived growth factor alpha-receptor as the binding site for Crk proteins.
Yokote K; Hellman U; Ekman S; Saito Y; Rönnstrand L; Saito Y; Heldin CH; Mori S
Show more

All other publications

Review: INTERNATIONAL JOURNAL OF CANCER. 2023;153(9):1556-1567
Safety and efficacy of immune checkpoint blockade in patients with advanced nonsmall cell lung cancer and brain metastasis
Tsakonas G; Ekman S; Koulouris A; Adderley H; Ackermann CJ; Califano R
Corrigendum: TARGETED ONCOLOGY. 2023;18(2):311
Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies (Jan, 10.1007/s11523-022-00941-7, 2023)
Popat S; Ahn M-J; Ekman S; Leighl NB; Ramalingam SS; Reungwetwattana T; Siva S; Tsuboi M; Wu Y-L; Yang JC-H
Review: TARGETED ONCOLOGY. 2023;18(1):9-24
Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies
Popat S; Ahn M-J; Ekman S; Leighl NB; Ramalingam SS; Reungwetwattana T; Siva S; Tsuboi M; Wu Y-L; Yang JC-H
Review: LIFE. 2022;12(6):880
Cancer Cachexia and Antitumor Immunity: Common Mediators and Potential Targets for New Therapies
Rounis K; Makrakis D; Gioulbasanis I; Ekman S; De Petris L; Mavroudis D; Agelaki S
Review: JOURNAL OF INTERNAL MEDICINE. 2022;291(6):732-754
Complications following novel therapies for non-small cell lung cancer
Skribek M; Rounis K; Tsakonas G; Ekman S
Review: TRANSLATIONAL LUNG CANCER RESEARCH. 2020;9(6):2535-2544
How selecting best therapy for metastatic NTRK fusion-positive non-small cell lung cancer?
Ekman S
Review: EUROPEAN JOURNAL OF CANCER. 2020;125:1-11
Immune checkpoint blockade for non-small cell lung cancer: What is the role in the special populations?
Califano R; Gomes F; Ackermann CJ; Rafee S; Tsakonas G; Ekman S
Review: JOURNAL OF THORACIC ONCOLOGY. 2019;14(6):968-978
Early-Stage NSCLC: Advances in Thoracic Oncology 2018
Osarogiagbon RU; Veronesi G; Fang W; Ekman S; Suda K; Aerts JG; Donington J
Editorial comment: ANNALS OF ONCOLOGY. 2019;30(3):353-355
HER2: defining a Neu target in non-small-cell lung cancer
Ekman S
Review: JOURNAL OF THORACIC DISEASE. 2018;10(Suppl 13):S1547-S1555
Oncogene-addicted non-small cell lung cancer and immunotherapy
Tsakonas G; Ekman S
Review: SURGICAL ONCOLOGY. 2017;26(3):290-295
Current trends in multimodality treatment of esophageal and gastroesophageal junction cancer - Review article
Klevebro F; Ekman S; Nilsson M
Review: CANCER TREATMENT REVIEWS. 2017;54:122-131
Management of brain metastasized non-small cell lung cancer (NSCLC) - From local treatment to new systemic therapies
Tsakonas G; De Petris L; Ekman S
Review: ANTICANCER RESEARCH. 2015;35(5):2493-2501
Randomized Trials of Systemic Medically-treated Malignant Mesothelioma: A Systematic Review.
Blomberg C; Nilsson J; Holgersson G; Edlund P; Bergqvist M; Adwall L; Ekman S; Brattström D; Bergström S
Review: ANTICANCER RESEARCH. 2012;32(9):4001-4006
A Review of Dose-dense Temozolomide Alone and in Combination with Bevacizumab in Patients with First Relapse of Glioblastoma
Johansson F; Ekman S; Blomquist E; Henriksson R; Bergstrom S; Bergqvist M
Corrigendum: JOURNAL OF CHROMATOGRAPHY B: ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES. 2012;889:148
Determination of picropodophyllin and its isomer podophyllotoxin in human serum samples with electrospray ionization of hexylamine adducts by liquid chromatography-tandem mass spectrometry (vol 879, pg 326, 2011)
Ronquist-Nii Y; Eksborg S; Axelson M; Harmenberg J; Ekman S; Bergqvist M; Beck O
Review: EXPERT OPINION ON THERAPEUTIC TARGETS. 2010;14(3):317-328
Hsp90 as a therapeutic target in patients with oesophageal carcinoma.
Ekman S; Bergqvist M; Tell R; Bergström S; Lennartsson J
Review: EXPERT REVIEW OF ANTICANCER THERAPY. 2008;8(9):1433-1448
Esophageal cancer: current and emerging therapy modalities.
Ekman S; Dreilich M; Lennartsson J; Wallner B; Brattström D; Sundbom M; Bergqvist M
Review: ONCOLOGIST. 2007;12(10):1165-1177
Activation of growth factor receptors in esophageal cancer--implications for therapy.
Ekman S; Bergqvist M; Heldin C-H; Lennartsson J
Review: ANTICANCER RESEARCH. 2007;27(5B):3545-3553
Clinical value of using serological cytokeratins as therapeutic markers in thoracic malignancies.
Ekman S; Eriksson P; Bergström S; Johansson P; Goike H; Gullbo J; Henriksson R; Larsson A; Bergqvist M

About me

Articles

All other publications

News from KI

Events from KI